Author | Harry Erba, MD, PhD | OncLive

Author | Harry Erba, MD, PhD

Articles

Dr. Erba Discusses Efficacy of CPX-351 in Additional Subsets of AML

August 25, 2017

Video

Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, discusses additional subsets of acute myeloid leukemia (AML) that CPX-351 (Vyxeos) demonstrates efficacy in.

Dr. Erba on Unique Characteristics of CPX-351 in AML

August 22, 2017

Video

Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, discusses unique characteristics of CPX-351 (Vyxeos) in acute myeloid leukemia (AML).

Dr. Erba on the FDA Approval of CPX-351 in AML

August 11, 2017

Video

Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, sheds light on the FDA approval of CPX-351 (Vyxeos) in acute myeloid leukemia (AML).

Dr. Erba on FLT3 Inhibitors for the Treatment of AML

April 02, 2014

Video

Harry Erba, MD, PhD, professor of medicine, director, Hematologic Malignancy Program, University of Alabama at Birmingham, discusses the excitement around FLT3 inhibitors for the treatment of acute myeloid leukemia (AML).

x